• where experts go to learn about FDA
  • Month: November 2017

    • Nevada Scares Diabetes Drug Manufacturers With Halloween List of “Essential Diabetes Drugs”November 9th, 2017

      In June, we reported on Nevada S.B 539, a new law that, among other things, requires manufacturers of “essential diabetes drugs” to report certain sensitive financial information concerning these drugs. On October 31, the Nevada Department of Health and Human Services took the first step …

    • NOP Issues Interim Instruction Regarding Organic ImportsNovember 7th, 2017

      As we previously reported, the integrity of imported organic products has been questioned. International supply chains are becoming increasingly “complex” and frequently involve a number of businesses which may be certified under different programs. Foreign organic operations are subject to the same requirements as domestic organic …

    • NOP Issues Interim Instruction Regarding Organic ImportsNovember 7th, 2017

      As we previously reported, the integrity of imported organic products has been questioned. International supply chains are becoming increasingly “complex” and frequently involve a number of businesses which may be certified under different programs. Foreign organic operations are subject to the same requirements as domestic organic …

    • FTC Releases FY 2015 Staff Report on Drug Patent Settlement Agreements; Competitive DRUGS Act of 2017 Introduced in HouseNovember 6th, 2017

      Last week, the Federal Trade Commission (“FTC”) announced the issuance of the Bureau of Competition’s annual summary of agreements filed with the Commission during the last fiscal year (Fiscal Year 2015) – Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, …

    • Sixth Circuit Affirms Dismissal of Off-Label Promotion FCA Case for Lack of Rule 9(b) SpecificityNovember 6th, 2017

      The Sixth Circuit recently dealt another blow to relators seeking damages under the False Claims Act (FCA) based on allegations of off-label promotion. In a 2-1 decision, the court, in United States ex rel. Ibanez v. Bristol-Myers Squibb Co., affirmed the district court’s dismissal of …

    • 2017: A Banner Year for State Laws on Drug Pricing, Price Reporting, and DiscountingNovember 2nd, 2017

      Despite relative inaction on drug pricing at the federal level so far this year, 2017 has been a banner year for state legislation involving pharmaceutical pricing, price reporting, and discounting. Because it is becoming increasingly difficult to keep track of these recent laws, we thought …

    • “Mutual Recognition” Kicks Into High GearNovember 1st, 2017

      On October 31st, FDA made its long anticipated announcement recognizing the first European drug regulatory authorities capable of conducting inspections of manufacturing facilities that meet FDA requirements. The eight countries that were announced are: Austria, Croatia, France, Italy, Malta, Spain, Sweden and the United Kingdom. The …

    • Citizen Petition to Declare Pyridoxamine Not Excluded from the Dietary Supplement DefinitionNovember 1st, 2017

      I understand if this title made you think for a minute, did I read that right? You probably did. Another Citizen Petition regarding pyridoxamine was filed. This one asks that FDA essentially undo what it did in 2009. Pyridoxamine is a form of vitamin B6. In July …